Beike Biotech

TAIZHOU, Jiangsu, China, January 6 – The Jiangsu Government’s Science and Technology Department has announced a $1.8 million grant - the Jiangsu Technological Achievements Transformational Grant - to support the research and development of human umbilical cord mesenchymal stem cell (hUC-MSC) technologies. The grant recipient and administrator, Shenzhen Beike Biotechnology Co., Ltd. (http://www.beikebiotech.com), is working with Jiangsu University and Nanjing University’s Drum Tower Hospital to fulfill the grant’s requirements.

This grant marks the start of the second stage of Beike’s stem cell engineering industrialization project. The project’s first phase began in May 2008, when Beike opened an 1,800 square-meter stem cell bank in Taizhou’s China Medical City district. In the second phase, the bank will be used as a library for storing and indexing hUC-MSC samples. In April 2009, Beike broke ground on its 20,000 square-meter Stem Cell Regenerative Medicine Industrial Complex, the world’s largest stem cell storage and processing facility. Beike will use a portion of the Jiangsu Technological Achievements Transformational Grant to outfit this complex with over 80 specialized pieces of equipment including fully automated enzyme immunoassay analysis systems, carbon dioxide incubators, and cell viability analyzers.

    NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.D., Ph.D., Chief Science Officer at Shenzhen Beike Biotechnology Co. Ltd. (http://www.beikebiotech.com ), spoke at a conference on High-Risk Diabetic Foot Care in New Delhi, India, November 22, 2009. Beike is China's leading stem cell research and regenerative medicine company.

      The conference, organized by the Indian Podiatry Association (IPA), aimed to help podiatrists and researchers with an interest in foot disease to "update, interact, modernize and catch up with the advancing pace of scientific development in the field of podiatry." Dr. Jiang's talk, titled "Umbilical Cord Mesenchymal Stem Cell and Clinical Application Prospects in Diabetic Foot Disease," outlined the promise of stem cells in the healing of diabetic wounds and diabetic foot pathology.

        "I am excited to have had this opportunity to discuss the role that stem cell therapy can play in healing diabetic wounds and related foot conditions," said Dr. Susan Jiang, speaking after the Conference. "India is one of the first countries to put forth clear and practical guidelines on the clinical use of stem cells. It has also been at the forefront in embracing this new technology, and utilizing its potential clinical applications. Together with leading clinicians in the field, Beike India is preparing a clinical trial of stem cell treatment in diabetic foot disease. Our pilot studies in China suggest that stem cell treatment will become a very practical and effective clinical intervention. We are happy to share our observations from our stem cell therapy studies with the Indian clinical community."

SHENZHEN, China, Nov. 4 /PRNewswire-Asia/ -- Shenzhen Beike Biotechnology Co. Ltd.

(http://www.beikebiotech.com ), China's leading stem cell research and regenerative medicine company, announced that it has entered into an agreement with Yokohama-based Biomaster Inc.

(http://www.biomaster.jp ) for investment in its advanced technologies.  Biomaster specializes in research and commercialization of adipose-based stem cell therapies. Beike, along with two investment companies, has taken a significant share in Biomaster, secured a seat on the board, and is involved in the company's strategic positioning in preparation for an eventual IPO.

    Since its inception in 2002, Biomaster has been a leading innovator in the field of adipose-derived stem cell regenerative technology. The company developed its proprietary Cell-Assisted Lipotransfer (CAL) procedure through joint research with the Plastic and Reconstructive Surgery Department at the University of Tokyo's Graduate School of Medicine. Biomaster's scientists have published ten articles in leading international journals related to stem cell technology.

SHENZHEN, China, Sept. 8 /PRNewswire-Asia/ -- Shenzhen Beike Biotechnology Co. Ltd. (www.beikebiotech.com), a leader in stem cell research and regenerative medicine, announced the appointment of two senior stem cell scientists to key positions in the company. Li Tao, Ph.D., joins as Lab Director of the iPS (induced Pluripotent Stem Cell) Laboratory, and Susan Jiang, M.D., Ph.D., has been named Chief Science Officer. Dr. Sean Hu, Ph.D., CEO and Chairman, will remain focused on furthering the company's research achievements while strengthening its position in the international biotechnology field.
    Dr. Hu commented, "Beike has been at the forefront of stem cell technology in China and we are currently expanding throughout Asia. We are addressing a number of important factors to strengthen our credentials internationally, and we see Dr. Li Tao and Dr. Susan Jiang contributing greatly to this effort. Dr. Jiang will spearhead our initiatives to enhance our current technologies and increase their acceptance by the Western scientific community while Dr. Tao will lead a group developing a pipeline of emerging technologies for the coming five to ten years."